Acusphere - Worst Pharma Stocks of 2007

Company: Acusphere
Starting stock price: $2.51
Ending stock price: $0.65
Percent Change: -74.10%

Details: Acusphere is focused on developing drugs using its microsphere technology. Its lead candidate is Imagify, an injectable for use during ultrasound or echocardiograms; it's designed to show perfusion, an indicator of heart disease. Its second Phase III trials of the compound were announced in May 2007 and the company is working with the FDA on a New Drug Application, which would require its manufacturing facility in Massachusetts to be certified. It expects to submit the NDA early this year.

Acusphere - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.